EP1781322A4 - Verfahren zur behandlung von diabetes - Google Patents

Verfahren zur behandlung von diabetes

Info

Publication number
EP1781322A4
EP1781322A4 EP05769913A EP05769913A EP1781322A4 EP 1781322 A4 EP1781322 A4 EP 1781322A4 EP 05769913 A EP05769913 A EP 05769913A EP 05769913 A EP05769913 A EP 05769913A EP 1781322 A4 EP1781322 A4 EP 1781322A4
Authority
EP
European Patent Office
Prior art keywords
treating diabetes
diabetes
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05769913A
Other languages
English (en)
French (fr)
Other versions
EP1781322A1 (de
Inventor
Andrew Jeremy Dunbar
Christopher Goddard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Biopharma AU Ltd
Original Assignee
Novozymes Biopharma AU Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Biopharma AU Ltd filed Critical Novozymes Biopharma AU Ltd
Publication of EP1781322A1 publication Critical patent/EP1781322A1/de
Publication of EP1781322A4 publication Critical patent/EP1781322A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP05769913A 2004-08-06 2005-08-05 Verfahren zur behandlung von diabetes Withdrawn EP1781322A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59905004P 2004-08-06 2004-08-06
PCT/AU2005/001180 WO2006012707A1 (en) 2004-08-06 2005-08-05 Method for treating diabetes

Publications (2)

Publication Number Publication Date
EP1781322A1 EP1781322A1 (de) 2007-05-09
EP1781322A4 true EP1781322A4 (de) 2009-09-30

Family

ID=35786836

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05769913A Withdrawn EP1781322A4 (de) 2004-08-06 2005-08-05 Verfahren zur behandlung von diabetes

Country Status (4)

Country Link
EP (1) EP1781322A4 (de)
JP (1) JP2008509093A (de)
CN (1) CN101090732A (de)
WO (1) WO2006012707A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23526B6 (es) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
KR20150138225A (ko) * 2013-03-12 2015-12-09 에이치엠아이 메디칼 이노베이션즈, 엘엘씨 항당뇨병성 및 다른 유용한 활성을 갖는 식물 추출물
KR102027750B1 (ko) * 2018-05-03 2019-10-02 연세대학교 산학협력단 당 배출용 조성물
WO2021002645A1 (ko) * 2019-07-01 2021-01-07 연세대학교 산학협력단 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물
CN110279860A (zh) * 2019-07-31 2019-09-27 上海交通大学医学院附属瑞金医院 Nrg4作为靶点在制备糖尿病药物中的应用
KR102109385B1 (ko) * 2019-08-21 2020-05-12 연세대학교 산학협력단 당 배출용 조성물
CN114075272B (zh) * 2020-08-10 2023-09-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1148129B1 (de) * 1998-12-09 2007-07-25 Takeda Pharmaceutical Company Limited Betacellulin-veränderung
JP4794049B2 (ja) * 1999-04-06 2011-10-12 ジェネンテック， インコーポレイテッド 糖尿病治療へのＥｒｂＢレセプターリガンドの使用
AUPQ496900A0 (en) * 2000-01-06 2000-02-03 Gropep Pty Ltd Growth factor splice variant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUNBAR A J ET AL: "Structure-function and biological role of betacellulin", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, EXETER, GB, vol. 32, no. 8, 1 August 2000 (2000-08-01), pages 805 - 815, XP002284781, ISSN: 1357-2725 *
ITOH T ET AL: "Novel betacellulin derivatives. Separation of the differentiation activity from the mitogenic activity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 276, no. 44, 2 November 2001 (2001-11-02), pages 40698 - 40703, XP002326603, ISSN: 0021-9258 *
OGATA TAKEKI ET AL: "Betacellulin-delta 4, a novel differentiation factor for pancreatic beta-cells, ameliorates glucose intolerance in streptozotocin-treated rats", ENDOCRINOLOGY, vol. 146, no. 11, November 2005 (2005-11-01), pages 4673 - 4681, XP002540696, ISSN: 0013-7227 *
See also references of WO2006012707A1 *

Also Published As

Publication number Publication date
EP1781322A1 (de) 2007-05-09
WO2006012707A1 (en) 2006-02-09
CN101090732A (zh) 2007-12-19
JP2008509093A (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
IL179325A0 (en) Method for treating lupus
IL181922A0 (en) Method for treating vasculitis
IL183889A0 (en) Treatment method
IL179139A0 (en) Method for treating multiple sclerosis
GB0402639D0 (en) Method
EP1781322A4 (de) Verfahren zur behandlung von diabetes
EP1809276A4 (de) Behandlungsverfahren
GB0410478D0 (en) Method
IL185555A0 (en) Method and composition for treating diabetes
GB0422533D0 (en) Non-aqueous treatment method
ZA200706456B (en) Method for treating liquids
GB0608357D0 (en) Method for treating effluent
GB0412659D0 (en) Method
GB0412672D0 (en) Method
GB0414787D0 (en) Method
AU2003299652A8 (en) Methods for treating diabetes
ZA200609978B (en) Method for treating lupus
GB0405751D0 (en) Method
TWI315261B (en) Method for transferring-printing
PL366494A1 (en) Method for obtaining 5-nitroguaiacol
GB0413714D0 (en) Method
GB0406103D0 (en) Treatment method
ZA200500148B (en) Method for nano-sizing
PL367566A1 (en) Method for sludge treatment
GB0412243D0 (en) Method for selectively treating a well

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVOZYMES GROPEP LIMITED

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVOZYMES BIOPHARMA AU LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 20090827

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091126